Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Robin Epplen"'
4
Wechsel des LHRH-Analogons beim progredienten kastrationsresistenten Prostatakarzinom
Autor: Axel Heidenreich, Daniel Porres, David Pfister, Robin Epplen, T. van Erps
Publikováno v: Der Urologe. 51:1282-1287
Hintergrund Standardtherapie des metastasierten Prostatakarzinoms (PCA) ist die medikamentose oder chirurgische Kastration – 2–12% der Patienten erreichen dieses Ziel nach medikamentoser Kastration jedoch nicht. Wir untersuchten, ob ein Wechsel d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e30c25d665be3dbd6d57744d0213fa9b
https://doi.org/10.1007/s00120-012-2948-9
Zobrazit plný text záznamu
5
Do α‑reductase inhibitors prevent prostate cancer? 2008 Practice Guideline from the American Society of Clinical Oncology and American Urological Association
Autor: David G. Pfister, Robin Epplen, Axel Heidenreich, Bernhard Brehmer, D. Thüer
Publikováno v: Polish Archives of Internal Medicine. 119:648-653
As new guidelines on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention produced by the American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) have recently been published, the use of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc56724fa050c76453e77c6286ea72cf
https://doi.org/10.20452/pamw.795
Zobrazit plný text záznamu
6
Sextant-Specific Analysis of Detection and Tumor Volume by HistoScanning™
Autor: Daniel Porres, Till Braunschweig, Timur H. Kuru, Samir Afram, Lieven Niels Kennes, Andreas Eck, David G. Pfister, Ruth Knüchel-Clarke, Robin Epplen, Vahudin Zugor, Axel Heidenreich
Publikováno v: Urologia internationalis. 96(2)
Introduction: Published results of HistoScanning™ (HS) for prostate cancer (PCa) diagnostics are inconsistent and their value remains unclear. We prospectively analyzed the detection rate and tumor volume concordance in PCa patients. Material and M
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fb3f1384c787591be47002c6d80e93
https://pubmed.ncbi.nlm.nih.gov/26555799
Zobrazit plný text záznamu
9
Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines
Autor: C. H. Ohlmann, Robin Epplen, Axel Heidenreich, Udo Engelmann, Michael Stöckle
Publikováno v: Acta oncologica (Stockholm, Sweden). 50(1)
Ibandronate, one of the most potent bisphosphonates, has been shown to inhibit growth of various cancer cell lines. In contrast, little is known about the effects of ibandronate on prostate cancer cells. Therefore the aim of our study was to characte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d0a13da65e8897de2d9f72a5a5d497
https://pubmed.ncbi.nlm.nih.gov/20429730
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje